Fatale Nebenwirkungen durch Downregulation?

Re: Fatale Nebenwirkungen durch Downregulation?

heiker,
ich hatte Dir schon einmal geschrieben, dass ich persönlich Deine Argumentation zweifelhaft sehe.
Du greifst hier unseren Dr.K. fast an. Das ist das allerletzte. Wir sind froh ihn kostenlos und uneigennützig zu haben. Er hat hier schon mit vielen Ratschlägen und Meinungen sooooooooo geholfen.
Bitte lass das!!

Re: Fatale Nebenwirkungen durch Downregulation?

Lieber Herr K.
nach welchen Medikamenten und Wirkstoffen habe Sie gesucht? Z.B. bei Zoladex, 3.75 mg findet man 2 Knochenmetastasen und 1 Throat Cancer. Daneben Nierenversagen, Herzinfarkte, Schilddrüsenprobleme, Tremor, Muskelzuckeungen, Neuropathien, Migräne; Depressionen, Schwächegefühl, Schmerzen, etc....es ist irgendwie alles dabei.

Bei 190 Berichten gab es 49 Tote (wahrscheinlich aber alles ältere Männer, leider fehlen die Altersangaben oft.) Vielleicht wären die ohnehin an Prostatakarzinom gestorben, wer weiss das schon...

Leute, schaut selbst, verlasst euch nicht auf irgendjemanden, auch nicht auf mich. Wie ihr sehen könnt, gibt es keinen 100%-igen Beweis. Den kann es auch nicht geben, in der Medizin arbeitet man immer mit Wahrscheinlichkeiten. Und ehrlich gesagt, über diese Wahrscheinlichkeiten möchte ich informiert werden!

Die EMA hat im übrigen die Hersteller aufgefordert, über das erhöhte Risiko, nach GnRH an schweren Depression zu erkranken, zu informieren. Das war Dez. 2011.

LG
heiker

Australische NW Berichte zu Zoladex (bitte selbst runterladen, ich weiss das ganze ist jetzt hier wie ich es einstellen kann, schlecht lesbar.:

Results
Number of reports (cases): 190
(Multiple adverse events have been reported for some patients)
Number of cases with a single suspected medicine: 149
(The TGA thinks there is a possibility that the medicine caused the adverse event)
Number of cases where death was a reported outcome: 49
(These reports of death may or may not have been a result of taking a medicine)
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00059063 28/02/1989 28 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Drug ineffective
Renal failure
acute
•
AU00068990 17/12/1990 - M Androcur (Cyproterone Acetate) -
Suspected
•
• Not specified (Thiamine) - Suspected
• Pepcidine (Famotidine) - Suspected
Stemetil (Prochlorperazine Maleate) -
Suspected
•
• Ventolin (Salbutamol) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Chills
• Convulsion
• Headache
AU00069598 15/02/1991 38 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Hot flush
AU00073663 21/10/1991 64 M Zoladex Implant (Goserelin Acetate) -
Suspected
• Blood alkaline
phosphatase
increased
•
• Gynaecomastia
• Spider naevus
AU00076915 11/05/1992 - M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Not specified (Flutamide) - Not
suspected
•
• Bronchospasm
• Cough
• Rhinitis
Report generated 8/10/2012 12:48:28 AM Page 3 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00082994 22/02/1993 - M Androcur (Cyproterone Acetate) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Amnesia
• Ataxia
Consciousness
fluctuating
•
• Delirium
• Dementia
Disturbance in
attention
•
Faecal
incontinence
•
• Gait disturbance
Urinary
incontinence
•
AU00085507 24/06/1993 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Rash maculopapular
•
AU00090804 31/01/1994 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Diabetes
mellitus
•
AU00091097 16/02/1994 - M • Not specified (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Hepatic function
abnormal
•
AU00094043 28/06/1994 - M • Eulexin (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Haemolysis
AU00094304 08/07/1994 - M • Daonil (Glibenclamide) - Suspected
• Eulexin (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Diabetes
mellitus
•
• Hyperhidrosis
• Pyrexia
AU00095977 19/09/1994 35 F Zoladex Implant (Goserelin Acetate) -
Suspected
• Uterine
haemorrhage
•
AU00096045 26/09/1994 - - Zoladex Implant (Goserelin Acetate) -
Suspected
• Weight
increased
•
Report generated 8/10/2012 12:48:28 AM Page 4 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00096313 06/10/1994 - F • Coversyl (Perindopril) - Suspected
Diabex (Metformin Hydrochloride) -
Suspected
•
• F.G.F, (F.g.f.) - Suspected
Isoptin (Verapamil Hydrochloride) -
Suspected
•
• Lanoxin (Digoxin) - Suspected
• Not specified (Frusemide) - Suspected
Primolut-n (Norethisterone) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Prothrombin
level increased
•
AU00097497 01/12/1994 - M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Renitec (Enalapril Maleate) - Not
suspected
•
• Serepax (Oxazepam) - Not suspected
Voltaren (Diclofenac Sodium) - Not
suspected
•
Photosensitivity
reaction
•
AU00097539 05/12/1994 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Fatigue
• Myalgia
AU00098032 29/12/1994 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Injection site
necrosis
•
AU00098298 12/01/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Alopecia
AU00098742 06/02/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Abdominal pain
• Asthenia
• Hot flush
• Nausea
• Syncope
• Tremor
• Vomiting
AU00098920 13/02/1995 - F Not specified (Sandocal 1000) -
Suspected
•
Premarin (Oestrogens Conjugated) -
Suspected
•
Provera (Medroxyprogesterone
Acetate) - Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Pathological
fracture
•
Report generated 8/10/2012 12:48:28 AM Page 5 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00099262 28/02/1995 74 M • Not specified (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Not specified (Calcium Carbonate) -
Not suspected
•
Not specified (Ferrous Sulphate) - Not
suspected
•
Not specified (Warfarin Sodium) - Not
suspected
•
Vitamin B Group And C Injection
(Vitamin Preparation Compound) - Not
suspected
•
• Flatulence
AU00099458 08/03/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Pain
AU00099477 15/03/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Hypopituitarism
AU00099810 27/03/1995 45 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Abdominal pain
Vaginal
haemorrhage
•
AU00101281 29/05/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Hypercholesterol
aemia
•
AU00101203 30/05/1995 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Depression
Erectile
dysfunction
•
• Hot flush
• Insomnia
Libido
decreased
•
AU00101251 31/05/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Alopecia
AU00101835 30/06/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Acne
• Drug ineffective
• Ovarian cyst
Uterine
haemorrhage
•
AU00102875 14/08/1995 29 F Zoladex Implant (Goserelin Acetate) -
Suspected
• Ovarian
hyperstimulation
syndrome
•
Vaginal
haemorrhage
•
Report generated 8/10/2012 12:48:28 AM Page 6 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00102943 17/08/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
•
Premarin (Oestrogens Conjugated) -
Not suspected
•
Theo-dur (Theophylline) - Not
suspected
•
• Ventolin (Salbutamol) - Not suspected
• Optic neuritis
Visual
impairment
•
AU00103470 11/09/1995 83 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Pruritus
• Rash
AU00103632 20/09/1995 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Dizziness
• Dysgeusia
• Paraesthesia
• Pruritus
AU00104038 16/10/1995 70 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Rash
AU00104808 23/11/1995 - M Cardizem (Diltiazem Hydrochloride) -
Suspected
•
Imdur (Isosorbide Mononitrate) -
Suspected
•
Nitradisc (Glyceryl Trinitrate) -
Suspected
•
Not specified (Enalapril Maleate) -
Suspected
•
• Not specified (Frangula) - Suspected
Not specified (Senna Fruit) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Hepatic function
abnormal
•
AU00104925 28/11/1995 - M Androcur (Cyproterone Acetate) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Hepatic failure
AU00104942 28/11/1995 - M • Lasix (Frusemide) - Suspected
Minipress (Prazosin Hydrochloride) -
Suspected
•
Not specified (Amiodarone
Hydrochloride) - Suspected
•
• Not specified (Flutamide) - Suspected
Renitec (Enalapril Maleate) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Asthenia
• Cough
• Dyspnoea
• Hypoaesthesia
• Hypoxia
• Pain
Pulmonary
fibrosis
•
Skin
discolouration
•
Report generated 8/10/2012 12:48:28 AM Page 7 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00106581 21/02/1996 40 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Anxiety
AU00107214 19/03/1996 24 F Zoladex Implant (Goserelin Acetate) -
Suspected
•
Becloforte (Beclomethasone
Dipropionate) - Not suspected
•
Electroencephal
ogram abnormal
•
• Sleep disorder
Thinking
abnormal
•
AU00107411 28/03/1996 35 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Arthralgia
AU00110182 24/07/1996 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Injection site
pain
•
AU00110649 08/08/1996 - M • Eulexin (Flutamide) - Suspected
• Proscar (Finasteride) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Dyspnoea
• Eosinophilia
Eosinophilic
pneumonia
•
AU00111514 09/09/1996 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Arthralgia
• Constipation
• Cough
Decreased
appetite
•
• Eosinophilia
Eosinophilic
pneumonia
•
• Fatigue
• Myalgia
Red blood cell
sedimentation
rate increased
•
Thrombocytopen
ia
•
AU00111540 09/09/1996 - M • Eulexin (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Arthralgia
• Arthritis
AU00112429 21/10/1996 - M • Eulexin (Flutamide) - Suspected
• Not specified (Aspirin) - Suspected
• Not specified (Perindopril) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Anaemia
• Fatigue
AU00112492 24/10/1996 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Aggression
• Depression
• Migraine
Report generated 8/10/2012 12:48:28 AM Page 8 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00113196 15/11/1996 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Bronchospasm
AU00114547 15/01/1997 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Unintended
pregnancy
•
AU00115045 06/02/1997 - M • Eulexin (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Dyspepsia
• Malaise
AU00115364 17/02/1997 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Hypertension
AU00116236 21/03/1997 - M • Cosudex (Bicalutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Androcur (Cyproterone Acetate) - Not
suspected
•
Lucrin (Leuprorelin Acetate) - Not
suspected
•
• Norvasc (Amlodipine) - Not suspected
• Oedema
AU00117759 22/05/1997 - M Anginine (Glyceryl Trinitrate) -
Suspected
•
Cardizem Cd (Diltiazem
Hydrochloride) - Suspected
•
• Solprin (Aspirin Soluble) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Furuncle
AU00120819 15/09/1997 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Injection site
inflammation
•
AU00120940 18/09/1997 39 F Zoladex Implant (Goserelin Acetate) -
Suspected
• Injection site
inflammation
•
AU00121269 01/10/1997 62 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Hot flush
AU00121907 27/10/1997 - M • Anandron (Nilutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Dyspnoea
• Lung infiltration
Respiratory
failure
•
AU00122352 14/11/1997 - M Not specified (Bicalutamide) -
Suspected
•
• Not specified (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Diabetes
mellitus
•
Report generated 8/10/2012 12:48:28 AM Page 9 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00122696 24/11/1997 21 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Galactorrhoea
AU00124473 29/01/1998 - F Premarin (Oestrogens Conjugated) -
Suspected
•
Provera (Medroxyprogesterone
Acetate) - Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Galactorrhoea
AU00126439 06/04/1998 - M Anginine (Glyceryl Trinitrate) -
Suspected
•
Betamin (Thiamine Hydrochloride) -
Suspected
•
• Eulexin (Flutamide) - Suspected
• Not specified (Aspirin) - Suspected
Not specified (Famotidine) -
Suspected
•
Not specified (Isosorbide Mononitrate)
- Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Cardiac arrest
AU00126744 17/04/1998 - M • Anandron (Nilutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Isoptin SR (Verapamil Hydrochloride) -
Not suspected
•
• Not specified (Aspirin) - Not suspected
Pepcidine (Famotidine) - Not
suspected
•
• Zyloprim (Allopurinol) - Not suspected
Pulmonary
fibrosis
•
AU00127349 12/05/1998 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Injection site
reaction
•
• Oedema
• Pruritus
• Rash
AU00129517 24/07/1998 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Depression
AU00130807 07/09/1998 - F Not specified (Somatropin) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Minitran (Glyceryl Trinitrate) - Not
suspected
•
• Hirsutism
Report generated 8/10/2012 12:48:28 AM Page 10 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00135194 18/01/1999 73 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Agitation
• Depression
• Hot flush
Personality
disorder
•
AU00137296 16/03/1999 - M • Amfamox (Famotidine) - Suspected
• Lipex (Simvastatin) - Suspected
Not specified (Verapamil
Hydrochloride) - Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Diabetes
mellitus
•
AU00140411 10/06/1999 - M Not specified (Goserelin Acetate) -
Suspected
• • Hyperglycaemia
AU00142076 29/07/1999 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Alopecia
AU00149663 25/02/2000 - M • Eulexin (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Atrial fibrillation
Myocardial
infarction
•
• Pneumonia
AU00150372 10/03/2000 - F Not specified (Amcal Strong Pain
Plus) - Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Arthralgia
Oedema
peripheral
•
AU00150334 13/03/2000 - M • Eulexin (Flutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Urinary retention
AU00161551 15/02/2001 - M • Cosudex (Bicalutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Not specified (Warfarin Sodium) - Not
suspected
•
Polymyalgia
rheumatica
•
AU00166420 11/07/2001 - M Androcur (Cyproterone Acetate) -
Suspected
•
Honvan (Fosfestrol Tetrasodium) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Coagulopathy
• Haemorrhage
Haemorrhage
intracranial
•
• Headache
• Nausea
• Purpura
AU00167279 01/08/2001 45 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Drug ineffective
Report generated 8/10/2012 12:48:28 AM Page 11 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00169111 05/10/2001 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Blindness
Confusional
state
•
Haemorrhage
intracranial
•
• Headache
• Nausea
• Vomiting
AU00171674 02/01/2002 71 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Not specified (Calcitriol) - Not
suspected
•
Not specified (Prednisolone) - Not
suspected
•
Not specified (Ranitidine) - Not
suspected
•
Panadeine Forte (Paracetamolcodeine
Phosphate) - Not suspected
•
Renitec (Enalapril Maleate) - Not
suspected
•
• Paraesthesia
AU00171914 11/01/2002 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Gynaecomastia
AU00180181 30/10/2002 74 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Betaloc (Metoprolol Tartrate) - Not
suspected
•
Coversyl Plus (Indapamide
Hemihydrate-perindopril) - Not
suspected
•
• Ikorel (Nicorandil) - Not suspected
• Lipex (Simvastatin) - Not suspected
• Not specified (Aspirin) - Not suspected
Not specified (Omeprazole) - Not
suspected
•
• Pruritus
Rash maculopapular
•
AU00186377 29/05/2003 57 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Depression
• Suicide attempt
AU00186971 16/06/2003 - M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Androcur (Cyproterone Acetate) - Not
suspected
•
Not specified (Calcium Nos) - Not
suspected
•
• Not specified (Zinc) - Not suspected
Dermatitis
bullous
•
Report generated 8/10/2012 12:48:28 AM Page 12 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00188858 28/07/2003 39 F Zoladex Implant (Goserelin Acetate) -
Suspected
• Dermatitis
bullous
•
AU00188883 28/07/2003 25 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Urticaria
AU00192440 24/11/2003 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Depression
AU00196419 13/04/2004 72 M Zoladex Implant (Goserelin Acetate) -
Suspected
• Rash
erythematous
•
• Rash macular
AU00197481 20/05/2004 - M • Cosudex (Bicalutamide) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Dyspnoea
AU00201180 24/09/2004 - F Zoladex Implant (Goserelin Acetate) -
Suspected
•
Not specified (Tamoxifen Citrate) - Not
suspected
•
Psychotic
disorder
•
AU00203514 13/12/2004 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Alcohol
intolerance
•
• Arthralgia
• Fatigue
Micturition
disorder
•
• Paraesthesia
• Vomiting
Weight
increased
•
Report generated 8/10/2012 12:48:28 AM Page 13 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00203681 20/12/2004 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Adnexa uteri
pain
•
Confusional
state
•
Depersonalisatio
n
•
• Dizziness
• Endometriosis
Eustachian tube
obstruction
•
• Eye pain
• Headache
• Hyperaesthesia
• Hypoaesthesia
• Local reaction
• Mood swings
• Nausea
• Photophobia
Visual
impairment
•
AU00205171 11/02/2005 67 M Seretide Accuhaler Nos (Fluticasone
Propionate-salmeterol Xinafoate) -
Suspected
•
• Ventolin (Salbutamol) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Photodermatosis
AU00210410 05/08/2005 71 M Not specified (Cyproterone Acetate) -
Suspected
•
Not specified (Goserelin Acetate) -
Suspected
•
• Not specified (Aspirin) - Not suspected
Not specified (Atenolol) - Not
suspected
•
Not specified (Diltiazem
Hydrochloride) - Not suspected
•
• Asthenia
• Hepatitis
AU00210658 12/08/2005 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Myocardial
infarction
•
AU00213266 09/11/2005 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Arthralgia
Report generated 8/10/2012 12:48:28 AM Page 14 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00213536 17/11/2005 38 F Not specified (Goserelin Acetate) -
Suspected
• • Chest pain
Myocardial
infarction
•
Troponin
increased
•
AU00216413 10/03/2006 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Injection site
abscess
•
Injection site
cellulitis
•
AU00219974 13/07/2006 - F Zoladex Implant (Goserelin Acetate) -
Suspected
•
Oestradiol Implant (Oestradiol) - Not
suspected
•
• Depression
AU00220463 31/07/2006 63 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Aropax (Paroxetine Hydrochloride) -
Not suspected
•
Cosudex (Bicalutamide) - Not
suspected
•
Not specified (Combivir) - Not
suspected
•
Not specified (Indomethacin) - Not
suspected
•
Not specified (Nevirapine) - Not
suspected
•
Seretide Accuhaler Nos (Fluticasone
Propionate-salmeterol Xinafoate) - Not
suspected
•
• Ventolin (Salbutamol) - Not suspected
• Depression
AU00223277 17/11/2006 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Gravitational
oedema
•
• Rash
AU00228115 02/05/2007 - M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Coumadin (Warfarin Sodium) - Not
suspected
•
Isoptin (Verapamil Hydrochloride) -
Not suspected
•
• Lasix (Frusemide) - Not suspected
• Lipitor (Atorvastatin) - Not suspected
• Ramace (Ramipril) - Not suspected
Slow-k (Potassium Chloride) - Not
suspected
•
Pruritus
generalised
•
Report generated 8/10/2012 12:48:28 AM Page 15 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00232129 17/08/2007 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Deep vein
thrombosis
•
AU00232985 04/09/2007 - M • Cosudex (Bicalutamide) - Suspected
• Feldene (Piroxicam) - Suspected
Fosamax Once Weekly Tablets
(Alendronate Sodium) - Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Aristocort (Triamcinolone Acetonide) -
Not suspected
•
Elocon (Mometasone Furoate) - Not
suspected
•
• Gingivitis
• Lichen planus
Tongue
ulceration
•
AU00235335 15/11/2007 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Psychotic
disorder
•
AU00235337 15/11/2007 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Psychotic
disorder
•
AU00235456 20/11/2007 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Breast swelling
• Depression
• Headache
• Penis disorder
Testicular
disorder
•
Visual
impairment
•
• Vomiting
AU00238922 13/03/2008 - - Zoladex Implant (Goserelin Acetate) -
Suspected
• Pulmonary
embolism
•
AU00240092 16/04/2008 - M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Androcur (Cyproterone Acetate) - Not
suspected
•
Pituitary
haemorrhage
•
Sudden visual
loss
•
AU00240523 01/05/2008 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Phimosis
AU00240550 05/05/2008 75 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Testicular pain
AU00241307 28/05/2008 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Testicular pain
AU00241730 10/06/2008 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Polyarthritis
Report generated 8/10/2012 12:48:28 AM Page 16 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00241956 16/06/2008 68 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Pain
• Paraesthesia
AU00243434 04/08/2008 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Asthenia
Breast
tenderness
•
• Chills
Confusional
state
•
• Depression
Emotional
disorder
•
• Hot flush
• Hypogonadism
• Muscle twitching
• Nightmare
• Nipple pain
• Pubic pain
Visual
impairment
•
AU00243452 04/08/2008 - F Zoladex (Goserelin Acetate) -
Suspected
• • Sleep disorder
AU00244204 28/08/2008 - F • Herceptin (Trastuzumab) - Suspected
Zoladex Implant (Goserelin Acetate) -
Suspected
•
• Hypoaesthesia
Neuropathy
peripheral
•
AU00244757 19/09/2008 - M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Cosudex (Bicalutamide) - Not
suspected
•
Systolic
hypertension
•
AU00247051 10/12/2008 - M Not specified (Clopidogrel) -
Suspected
•
Zoladex Implant (Goserelin Acetate) -
Suspected
•
Injection site
haemorrhage
•
AU00249685 26/03/2009 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Hot flush
• Hyperhidrosis
AU00254369 23/07/2009 84 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Atacand (Candesartan Cilexetil) - Not
suspected
•
Not specified (Doxycycline
Hydrochloride) - Not suspected
•
• Plavix (Clopidogrel) - Not suspected
• Hypersensitivity
• Urticaria
Report generated 8/10/2012 12:48:28 AM Page 17 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00254502 26/07/2009 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Asthenia
• Fatigue
AU00261246 21/12/2009 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Rash
AU00270938 19/07/2010 - M Not specified (Cyproterone Acetate) -
Suspected
•
Not specified (Goserelin Acetate) -
Suspected
•
Not specified (Sotalol Hydrochloride) -
Suspected
•
Pituitary tumour
benign
•
AU00271591 02/08/2010 - - Not specified (Goserelin Acetate) -
Suspected
•
• Zometa (Zoledronic Acid) - Suspected
• Crying
Neoplasm
malignant
•
• Pain in extremity
Prostatic specific
antigen
increased
•
Weight
decreased
•
AU00272578 24/08/2010 77 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Dry skin
• Pruritus
AU00274114 05/10/2010 - M Not specified (Goserelin Acetate) -
Suspected
• • Dyspnoea
• Malaise
AU00276431 06/12/2010 - F Zoladex Implant (Goserelin Acetate) -
Suspected
• Autoimmune
hepatitis
•
• Off label use
AU00278501 09/02/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Disease
progression
•
Neoplasm
malignant
•
AU00279762 10/03/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Disease
progression
•
AU00281189 11/04/2011 88 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00281528 15/04/2011 89 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Leukaemia
• Pneumonia
• Renal failure
Report generated 8/10/2012 12:48:28 AM Page 18 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00281615 18/04/2011 70 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Not specified (Insulin Nos) - Not
suspected
•
• Headache
AU00282073 29/04/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Arterial disorder
• Metastasis
Visual acuity
reduced
•
AU00282225 03/05/2011 80 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Bicor (Bisoprolol Fumarate) - Not
suspected
•
Exforge Nos (Amlodipine-Valsartan) -
Not suspected
•
• Lasix (Frusemide) - Not suspected
• Cardiomegaly
Pulmonary
oedema
•
AU00282226 03/05/2011 76 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Caltrate (Calcium Carbonate) - Not
suspected
•
• Lipitor (Atorvastatin) - Not suspected
• Mobic (Meloxicam) - Not suspected
Not specified (Verapamil
Hydrochloride) - Not suspected
•
• Skin cancer
AU00282542 09/05/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Cerebrovascular
accident
•
• Cystitis
Gastrointestinal
infection
•
• Melaena
• Sepsis
AU00282547 09/05/2011 72 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Cardiac failure
• Hip fracture
• Hyperhidrosis
• Osteoporosis
AU00282589 10/05/2011 80 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Cardiac failure
Prostate cancer
metastatic
•
AU00283002 19/05/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Fall
Metastases to
bone
•
Report generated 8/10/2012 12:48:28 AM Page 19 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00283138 23/05/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• Myocardial
infarction
•
AU00283139 23/05/2011 72 M Zoladex Implant (Goserelin Acetate) -
Suspected
• Cerebrovascular
accident
•
AU00283360 27/05/2011 75 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Brain injury
Cerebrovascular
accident
•
• Fall
AU00285011 24/06/2011 75 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Fatigue
• Hot flush
Male sexual
dysfunction
•
Skin
discolouration
•
AU00285202 29/06/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Bladder cancer
Bladder
neoplasm
surgery
•
• Prostatectomy
AU00286426 26/07/2011 - M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Cardiac failure
Weight
increased
•
AU00286552 27/07/2011 88 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Cardiac failure
AU00287969 25/08/2011 81 M Zoladex Implant (Goserelin Acetate) -
Suspected
• Coronary artery
bypass
•
• Thrombosis
AU00288406 05/09/2011 47 M Zoladex Implant (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00289541 26/09/2011 - M Zoladex (Goserelin Acetate) -
Suspected
• • Arterial stenosis
Myocardial
infarction
•
AU00291304 02/11/2011 69 M Zoladex Implant (Goserelin Acetate) -
Suspected
•
Actrapid (Insulin Neutral) - Not
suspected
•
Novorapid (Insulin Aspart) - Not
suspected
•
Blood glucose
abnormal
•
Loss of
consciousness
•
Report generated 8/10/2012 12:48:28 AM Page 20 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00293336 15/12/2011 36 F Zoladex Implant (Goserelin Acetate) -
Suspected
• • Pruritus
Rash
generalised
•
AU00294411 10/01/2012 68 M Zoladex Implant (Goserelin Acetate) -
Suspected
• Blood glucose
increased
•
• Hot flush
Weight
increased
•
AU00294974 24/01/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Staphylococcal
infection
•
AU00295027 25/01/2012 74 M Zoladex (Goserelin Acetate) -
Suspected
• Pulmonary
thrombosis
•
AU00295179 30/01/2012 - F Zoladex (Goserelin Acetate) -
Suspected
• Maternal
exposure during
pregnancy
•
• Off label use
AU00295509 06/02/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Bone neoplasm
malignant
•
• Prostate cancer
AU00295510 06/02/2012 - M Zoladex (Goserelin Acetate) -
Suspected
•
• Not specified (Aspirin) - Not suspected
Symbicort Turbuhaler (Budesonide-
Eformoterol Fumarate Dihydrate) - Not
suspected
•
• Hot flush
• Hypertension
AU00295835 13/02/2012 63 M Zoladex (Goserelin Acetate) -
Suspected
• • Urinary retention
AU00296097 16/02/2012 82 M Zoladex (Goserelin Acetate) -
Suspected
• Haemoglobin
decreased
•
• Hot flush
AU00297839 23/03/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Prostate cancer
metastatic
•
AU00297841 23/03/2012 62 M Zoladex (Goserelin Acetate) -
Suspected
• • Rash
AU00297945 26/03/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Bladder cancer
AU00298375 02/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Injury
Report generated 8/10/2012 12:48:28 AM Page 21 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00298386 03/04/2012 64 M Not specified (Hydroxychloroquine
Sulphate) - Suspected
•
Not specified (Leflunomide) -
Suspected
•
Not specified (Prednisolone) -
Suspected
•
Zoladex (Goserelin Acetate) -
Suspected
•
• Coversyl (Perindopril) - Not suspected
Vitamin D Nos (Vitamin Preparation
Compound) - Not suspected
•
Small cell lung
cancer stage
unspecified
•
AU00298733 11/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Prostate cancer
metastatic
•
AU00298738 11/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00298739 11/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Disease
progression
•
• Hot flush
• Osteoarthritis
AU00298746 11/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Disease
progression
•
AU00298756 11/04/2012 86 M Zoladex (Goserelin Acetate) -
Suspected
• Disease
progression
•
• Groin pain
AU00298765 11/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Multi-organ
failure
•
AU00298888 13/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Neoplasm
progression
•
• Pneumonia
AU00298889 13/04/2012 74 M Zoladex (Goserelin Acetate) -
Suspected
• Neoplasm
progression
•
AU00299001 16/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Neoplasm
progression
•
AU00299004 16/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Neoplasm
progression
•
AU00299006 16/04/2012 71 M Zoladex (Goserelin Acetate) -
Suspected
• Myocardial
infarction
•
AU00299007 16/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Neoplasm
progression
•
Report generated 8/10/2012 12:48:28 AM Page 22 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00299009 16/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Myocardial
infarction
•
Neoplasm
progression
•
AU00299091 17/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00299107 17/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00299308 20/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Throat cancer
AU00299322 20/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Myositis
• Renal cancer
AU00299377 23/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Intestinal
perforation
•
• Malaise
AU00299378 23/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00299379 23/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Prostate cancer
metastatic
•
AU00299544 26/04/2012 87 M Zoladex (Goserelin Acetate) -
Suspected
• Basal cell
carcinoma
•
• Dizziness
• Joint stiffness
AU00299588 27/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Myocardial
infarction
•
AU00299675 30/04/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Prostate cancer
metastatic
•
AU00299974 07/05/2012 - F Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00300215 11/05/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00300225 11/05/2012 82 M Zoladex (Goserelin Acetate) -
Suspected
• • Prostate cancer
AU00301149 28/05/2012 63 M Zoladex (Goserelin Acetate) -
Suspected
• Multi-organ
failure
•
Weight
increased
•
Report generated 8/10/2012 12:48:28 AM Page 23 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Footnotes
i A unique number that permits reference to a particular case
ii The date that information from the original report was entered into the database
iii Age of patient at time of adverse event, '-' if unknown
iv Gender of patient, '-' if unknown
v Medicines reported to have been taken by the patient
vi A description of the adverse event as defined by the Medical Dictionary for Regulatory Activities (MedDRA). You can
use the MedlinePlus medical dictionary <http://www.nlm.nih.gov/medlineplus/mplusdictionary.html> to look up terms.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00301153 28/05/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Prostate cancer
metastatic
•
AU00301756 07/06/2012 - M • Cosudex (Bicalutamide) - Suspected
Zoladex (Goserelin Acetate) -
Suspected
•
Disease
progression
•
Prostate cancer
metastatic
•
Prostatic specific
antigen
increased
•
AU00301858 08/06/2012 - M Zoladex (Goserelin Acetate) -
Suspected
• Gastrointestinal
carcinoma
•
Report generated 8/10/2012 12:48:28 AM Page 24 of 24
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report

Re: Fatale Nebenwirkungen durch Downregulation?

hallo Heiker

Das ein patient "Throat cancer" bekommen hat waehrend der Behandlung mit Zoladex, was in der Kinderwunschbehandlung sowieso nicht benutzt werden sollte, ist nicht ungewoehnlich und hat wohl keinen kausalen Zusammenhang. Knochenmetastasen sind sekundaer zu einem anderm Krebs .

Also koennen wir in Ruhe schon mal Krebs abhaken.

Die meisten beschriebenen Nebenwirkungen sind nach Langzeitgebrauch was in der Kinderwunschbehandlung nicht ueblich ist.

Ihre Liste nennt alle moeglichen anderen Medikamente und nicht nur die Downregulierung.

In amerikanischer , australischer und suedafrikanischer Praxis wird meist Leuprolide Acetate und Synarel Nasenspray gebraucht und in therapeutischer Dosis sind Nebenwirkungen extrem selten.

Damit schliesse ich meine Sonntagstaetigkeit hier im Forum fuer heute ab

Gruss

Dr.K.

Re: Fatale Nebenwirkungen durch Downregulation?

[quote author=dtift link=topic=8140.msg129969#msg129969 date=1350225556]
heiker,
ich hatte Dir schon einmal geschrieben, dass ich persönlich Deine Argumentation zweifelhaft sehe.
Du greifst hier unseren Dr.K. fast an. Das ist das allerletzte. Wir sind froh ihn kostenlos und uneigennützig zu haben. Er hat hier schon mit vielen Ratschlägen und Meinungen sooooooooo geholfen.
Bitte lass das!!
[/quote]

Es nervt, bitte suche Dir doch eine andere Spamoase!

Re: Fatale Nebenwirkungen durch Downregulation?

Liebe dfit,

warum liesst Du meine Beiträge, wenn Sie Dich nerven? Das verstehe ich nicht.

@Dr. K,

in die Nebenwirkungsliste kommt ein Fall z.B. für Zoladex nur dann, wenn dieses Medikament unter Verdacht steht. Wenn es ein anderes gleichzeitig eingenommenes Medikament wäre, was unter Verdacht stehen würde, wäre es dort in der Liste enthalten. Und dann z.B. nicht bei Zoladex. Das steht auch auf der Seite der Behörde und ist international anerkanntes vorgehen.

Was meinen Sie mit Langzeitbehandlung? Unter Langzeitbehandlung verstehe ich, wenn die Behandlung zum Stoppen der Ovulation führt.
Einige lassen sich hier sogar mehrfach downregulieren und auch bei Endometriose z.B. wird nicht mehr als 6 x ein Depotpräparat geraten. Empfohlen wird es sowieso von vielen Ärzten nicht mehr bei Endo.

Das Nebenwirkungsprofil der GNRHs (Zoladex, Lupron, Decapeptyl, Synarela etc.) ist in etwa identisch, das sagt mir zumindest meine "Rote Liste".

Sie können den Krebs ja gern "abhaken". Die Betroffenen können das leider nicht.

Gruss
heiker

Re: Fatale Nebenwirkungen durch Downregulation?

@ alle

Hier noch die von Dr. K angsprochene Marke: Lupron (auch Lycrin) Leuprorelin Acetate:

Das Nebenwirkungsprofil ist leider auch nicht viel besser.

Wenn mehrere Medikamente genommen wurden, steht jeweils da, ob noch andere "suspected" werden.

Gruss
heiker

Results
Number of reports (cases): 113
(Multiple adverse events have been reported for some patients)
Number of cases with a single suspected medicine: 89
(The TGA thinks there is a possibility that the medicine caused the adverse event)
Number of cases where death was a reported outcome: 3
(These reports of death may or may not have been a result of taking a medicine)
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00052325 24/05/1988 - M Doloxene (Dextropropoxyphene
Napsylate) - Suspected
•
Lucrin (Leuprorelin Acetate) -
Suspected
•
• Not specified (Flutamide) - Suspected
Not specified (Warfarin Sodium) -
Suspected
•
Coombs positive
haemolytic
anaemia
•
AU00089705 07/12/1993 - F Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Human Menopausal
Gonadotrophin) - Suspected
•
Injection site
reaction
•
AU00089706 07/12/1993 - F Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Human Menopausal
Gonadotrophin) - Suspected
•
Injection site
reaction
•
AU00089707 07/12/1993 - F Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Human Menopausal
Gonadotrophin) - Suspected
•
Injection site
reaction
•
AU00092375 26/04/1994 - M Lucrin (Leuprorelin Acetate) -
Suspected
• Anaphylactoid
reaction
•
AU00092448 27/04/1994 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Urticaria
AU00093677 08/06/1994 - F Lucrin (Leuprorelin Acetate) -
Suspected
•
• Metrodin (Urofollitrophin) - Suspected
• Dizziness
• Malaise
• Nausea
Rash maculopapular
•
AU00096668 25/10/1994 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
• Eulexin (Flutamide) - Not suspected
• Face oedema
• Pruritus
Report generated leer12:12:55 AM Page 3 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00099062 21/02/1995 62 M Lucrin (Leuprorelin Acetate) -
Suspected
•
Cogentin (Benztropine Mesylate) - Not
suspected
•
Neulactil (Pericyazine) - Not
suspected
•
Not specified (Lithium Carbonate) -
Not suspected
•
Not specified (Oxazepam) - Not
suspected
•
Psychotic
disorder
•
AU00104211 27/10/1995 - - Lucrin (Leuprorelin Acetate) -
Suspected
•
Androcur (Cyproterone Acetate) - Not
suspected
•
Not specified (Morphine Nos) - Not
suspected
•
• Sorbilax (Sorbitol) - Not suspected
• Cardiac arrest
AU00105860 15/01/1996 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Asthenia
Injection site
pain
•
AU00106938 07/03/1996 - F Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
inflammation
•
Injection site
pain
•
AU00107941 17/04/1996 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Fixed eruption
Genital
ulceration
•
AU00109290 17/06/1996 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
• Not specified (Flutamide) - Suspected
• Oruvail SR (Ketoprofen) - Suspected
• Cataract
AU00112696 31/10/1996 - F Lucrin (Leuprorelin Acetate) -
Suspected
• Grand mal
convulsion
•
• Hypercalcaemia
Hyperproteinae
mia
•
AU00113120 13/11/1996 - - • Aprinox (Bendrofluazide) - Suspected
• Coversyl (Perindopril) - Suspected
Lucrin (Leuprorelin Acetate) -
Suspected
•
• Not specified (Flutamide) - Suspected
Anaemia
macrocytic
•
Report generated leer12:12:55 AM Page 4 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00116854 18/04/1997 - - Lucrin (Leuprorelin Acetate) -
Suspected
• Rash maculopapular
•
• Skin exfoliation
AU00118231 12/06/1997 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Arthralgia
• Myalgia
• Osteoarthritis
AU00121225 30/09/1997 35 F Lucrin (Leuprorelin Acetate) -
Suspected
• • Hyperhidrosis
• Nausea
• Tremor
AU00121371 06/10/1997 - F Lucrin (Leuprorelin Acetate) -
Suspected
•
• Metrodin (Urofollitrophin) - Suspected
• Naprosyn (Naproxen) - Not suspected
Panadol (Paracetamol) - Not
suspected
•
• Arthralgia
• Bone pain
• Dysphagia
AU00121934 27/10/1997 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Arthritis
• Back pain
AU00125806 17/03/1998 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Hypercalcaemia
AU00128002 01/06/1998 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
• Tazac (Nizatidine) - Suspected
• Anaemia
AU00128366 12/06/1998 86 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Anginine (Glyceryl Trinitrate) - Not
suspected
•
Cardizem (Diltiazem Hydrochloride) -
Not suspected
•
Not specified (Enalapril Maleate) - Not
suspected
•
Not specified (Frusemide) - Not
suspected
•
Not specified (Glyceryl Trinitrate) - Not
suspected
•
Not specified (Nizatidine) - Not
suspected
•
Not specified (Prazosin Hydrochloride)
- Not suspected
•
• Anaemia
Report generated leer12:12:55 AM Page 5 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00140694 18/06/1999 79 M Honvan (Fosfestrol Tetrasodium) -
Suspected
•
Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
• Cardiac failure
Pulmonary
embolism
•
AU00140719 21/06/1999 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
pain
•
• Myalgia
AU00140879 21/06/1999 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
pain
•
• Myalgia
AU00145186 29/10/1999 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Left ventricular
failure
•
AU00145187 29/10/1999 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Extrasystoles
AU00145188 29/10/1999 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Cardiomyopathy
AU00153160 29/05/2000 - M Aredia (Disodium Pamidronate) -
Suspected
•
Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Morphine Sulphate) -
Suspected
•
• Nausea
AU00154293 28/06/2000 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Hot flush
AU00156276 14/08/2000 - M • Eulexin (Flutamide) - Suspected
Lucrin (Leuprorelin Acetate) -
Suspected
•
• Anaemia
• Fatigue
• Herpes zoster
AU00158267 05/10/2000 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
reaction
•
AU00158288 05/10/2000 78 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Neuropathy
peripheral
•
AU00158952 30/10/2000 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Gynaecomastia
AU00168895 02/10/2001 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
Panadeine Forte (Paracetamolcodeine
Phosphate) - Not suspected
•
• Vioxx (Rofecoxib) - Not suspected
• Abscess
Report generated leer12:12:55 AM Page 6 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00175258 08/05/2002 - F • Gonal-f (Follitropin Alfa) - Suspected
Lucrin (Leuprorelin Acetate) -
Suspected
•
Synarel (Nafarelin Acetate) -
Suspected
•
Erythema
multiforme
•
AU00176841 04/07/2002 71 M Androcur (Cyproterone Acetate) -
Suspected
•
Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
• Hepatitis
AU00182882 14/02/2003 - - Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
• Noten (Atenolol) - Not suspected
Seretide Accuhaler Nos (Fluticasone
Propionate-salmeterol Xinafoate) - Not
suspected
•
• Dyspnoea
AU00183142 21/02/2003 - - Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Colchicine) - Not
suspected
•
• Arthritis
AU00185371 28/04/2003 73 M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Asasantin SR) - Not
suspected
•
• Zocor (Simvastatin) - Not suspected
Injection site
reaction
•
• Tenderness
AU00190070 01/09/2003 77 M Androcur (Cyproterone Acetate) -
Suspected
•
Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
• Hepatitis acute
AU00191334 16/10/2003 70 M • Cosudex (Bicalutamide) - Suspected
Lucrin (Leuprorelin Acetate) -
Suspected
•
• Cardiac failure
• Fluid retention
AU00195493 16/03/2004 68 - Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
pain
•
AU00198633 01/07/2004 75 - Lucrin (Leuprorelin Acetate) -
Suspected
• • Infection
AU00204377 21/01/2005 70 - Lucrin (Leuprorelin Acetate) -
Suspected
• • Eczema
• Rash
Type IV
hypersensitivity
reaction
•
• Urticaria
Report generated leer12:12:55 AM Page 7 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00205630 28/02/2005 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Purpura
AU00207613 05/05/2005 72 - Lucrin (Leuprorelin Acetate) -
Suspected
• • Angina unstable
Aortic valve
disease
•
Cerebrovascular
accident
•
• Dilatation atrial
Mitral valve
incompetence
•
Pulmonary
hypertension
•
AU00207616 05/05/2005 67 - Lucrin (Leuprorelin Acetate) -
Suspected
• • Cholecystitis
AU00212625 17/10/2005 66 - Lucrin (Leuprorelin Acetate) -
Suspected
• Neuropathy
peripheral
•
AU00212773 24/10/2005 - M • Cosudex (Bicalutamide) - Suspected
Lucrin (Leuprorelin Acetate) -
Suspected
•
• Neutropenia
AU00215098 19/01/2006 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
Efexor-XR (Venlafaxine
Hydrochloride) - Not suspected
•
• Dysuria
• Insomnia
• Suicidal ideation
AU00215512 02/02/2006 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Hypersensitivity
Rash maculopapular
•
• Urticaria
AU00215608 07/02/2006 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Zoledronic Acid) -
Suspected
•
• Chest pain
• Pyrexia
AU00215610 07/02/2006 62 - Lucrin (Leuprorelin Acetate) -
Suspected
• Obstructive
uropathy
•
• Renal pain
AU00217293 11/04/2006 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Vision blurred
Visual
impairment
•
AU00217813 01/05/2006 57 M Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
swelling
•
Report generated leer12:12:55 AM Page 8 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00218382 16/05/2006 77 M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Zoledronic Acid) -
Suspected
•
• Not specified (Aspirin) - Not suspected
Not specified (Celecoxib) - Not
suspected
•
Not specified (Salbutamol) - Not
suspected
•
• Ascites
Bacterial
infection
•
• Biliary sepsis
• Cholelithiasis
Hepatic
encephalopathy
•
• Hepatic mass
• Jaundice
• Pyrexia
Respiratory
failure
•
Sinus
tachycardia
•
AU00218394 16/05/2006 74 - Lucrin (Leuprorelin Acetate) -
Suspected
• Cerebrovascular
accident
•
AU00218991 06/06/2006 62 - Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Zoledronic Acid) - Not
suspected
•
• Carbuncle
• Furuncle
Injection site
reaction
•
Subcutaneous
abscess
•
AU00219099 13/06/2006 74 - Lucrin (Leuprorelin Acetate) -
Suspected
• • Amnesia
• Asthenia
Cerebrovascular
accident
•
AU00219930 12/07/2006 - M Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
reaction
•
AU00219965 12/07/2006 73 M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Zoledronic Acid) - Not
suspected
•
• Chest pain
AU00222271 09/10/2006 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
• Cartia (Aspirin) - Not suspected
Catapres (Clonidine Hydrochloride) -
Not suspected
•
• Lipitor (Atorvastatin) - Not suspected
Nexium (Esomeprazole Magnesium
Trihydrate) - Not suspected
•
Zoloft (Sertraline Hydrochloride) - Not
suspected
•
• Chest pain
• Dyspnoea
• Fatigue
• Muscle spasms
Report generated leer12:12:55 AM Page 9 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00223114 14/11/2006 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Lower
respiratory tract
infection
•
AU00225670 12/02/2007 67 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Obstructive
uropathy
•
Renal failure
acute
•
Urinary tract
infection
•
AU00225828 14/02/2007 63 M Lucrin (Leuprorelin Acetate) -
Suspected
• • Dizziness
• Feeling hot
• Hyperhidrosis
• Vision blurred
AU00229103 30/05/2007 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
haematoma
•
Injection site
necrosis
•
AU00229888 19/06/2007 87 M Lucrin (Leuprorelin Acetate) -
Suspected
• • Depression
Erectile
dysfunction
•
• Fatigue
Memory
impairment
•
• Meningitis
• Pollakiuria
Urinary
incontinence
•
AU00231723 09/08/2007 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
haematoma
•
Injection site
mass
•
Injection site
necrosis
•
• Muscle abscess
• Muscle necrosis
AU00232217 20/08/2007 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Flutamide) - Not
suspected
•
Anaphylactic
reaction
•
Report generated leer12:12:55 AM Page 10 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00234069 05/10/2007 69 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Budesonide) - Not
suspected
•
Not specified (Meloxicam) - Not
suspected
•
Not specified (Perindopril) - Not
suspected
•
Not specified (Salbutamol) - Not
suspected
•
Not specified (Thioridazine
Hydrochloride) - Not suspected
•
Not specified (Tiotropium) - Not
suspected
•
Acute
myocardial
infarction
•
Pulmonary
oedema
•
AU00234961 01/11/2007 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Drug ineffective
AU00235417 19/11/2007 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
pustule
•
Injection site
reaction
•
AU00239411 31/03/2008 76 M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Allopurinol) - Not
suspected
•
• Not specified (Aspirin) - Not suspected
Microcytic
anaemia
•
AU00240017 15/04/2008 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Pain
AU00243126 22/07/2008 75 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Acetic Acid) - Not
suspected
•
Not specified (Aminoglutethimide) -
Not suspected
•
Not specified (Amlodipine) - Not
suspected
•
Not specified (Cortisone) - Not
suspected
•
Not specified (Perindopril) - Not
suspected
•
Not specified (Zoledronic Acid) - Not
suspected
•
Acute coronary
syndrome
•
Acute
myocardial
infarction
•
Report generated leer12:12:55 AM Page 11 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00243450 04/08/2008 - F Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
reaction
•
AU00243583 07/08/2008 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Incorrect route of
drug
administration
•
AU00243792 13/08/2008 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Abscess
• Haematoma
AU00245292 09/10/2008 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Sciatica
AU00245710 21/10/2008 72 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Cyproterone Acetate) -
Suspected
•
• Jaundice
AU00249538 23/03/2009 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Arrhythmia
Rash
generalised
•
AU00251093 18/05/2009 - F Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Chorionic
Gonadotrophin) - Not suspected
•
Not specified (Follitropin Alfa) - Not
suspected
•
Not specified (Somatropin) - Not
suspected
•
• Pneumonia
AU00252013 09/06/2009 - F Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Hypersensitivity
• Skin ulcer
AU00253674 13/07/2009 6 F Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
reaction
•
AU00254089 19/07/2009 33 F Lucrin (Leuprorelin Acetate) -
Suspected
•
Gonal-f (Follitropin Alfa) - Not
suspected
•
Not specified (Folic Acid) - Not
suspected
•
• Muscle twitching
Muscular
weakness
•
• Myalgia
• Oedema
Report generated leer12:12:55 AM Page 12 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00254703 30/07/2009 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Dysuria
Emotional
distress
•
• Eye pain
• Eyelid disorder
• Gait disturbance
• Haematochezia
Impaired driving
ability
•
Injection site
pain
•
• Insomnia
• Paraesthesia
• Scrotal pain
Visual
impairment
•
AU00255140 08/08/2009 68 F Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Myocardial
infarction
•
AU00261562 05/01/2010 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Drug ineffective
Histology
abnormal
•
AU00265916 28/04/2010 77 - Lucrin (Leuprorelin Acetate) -
Suspected
• Anaphylactic
reaction
•
AU00267113 12/05/2010 - M Fluvax (Influenza Vaccine) -
Suspected
•
Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Guillain-Barre
syndrome
•
AU00275415 10/11/2010 - M Lucrin (Leuprorelin Acetate) -
Suspected
• Loss of
consciousness
•
AU00275772 19/11/2010 - M Lucrin (Leuprorelin Acetate) -
Suspected
• Injection site
pain
•
Injection site
swelling
•
AU00275944 24/11/2010 83 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Lisinopril) - Not
suspected
•
Not specified (Moxonidine) - Not
suspected
•
Blood pressure
increased
•
Micturition
urgency
•
Report generated leer12:12:55 AM Page 13 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00280867 05/04/2011 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Deep vein
thrombosis
•
Lung neoplasm
malignant
•
Metastases to
bone
•
Metastatic
squamous cell
carcinoma
•
• Pleural effusion
• Pulmonary mass
AU00281100 08/04/2011 60 M Lucrin (Leuprorelin Acetate) -
Suspected
• Application site
reaction
•
• Cold sweat
• Dizziness
• Fatigue
• Vomiting
AU00284775 21/06/2011 - M Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Warfarin Sodium) -
Suspected
•
International
normalised ratio
increased
•
AU00284836 22/06/2011 75 - Lucrin (Leuprorelin Acetate) -
Suspected
•
Not specified (Zoledronic Acid) -
Suspected
•
Cortate (Cortisone Acetate) - Not
suspected
•
• Coversyl (Perindopril) - Not suspected
Nexium (Esomeprazole Magnesium
Trihydrate) - Not suspected
•
• Norvasc (Amlodipine) - Not suspected
Not specified (Clopidogrel) - Not
suspected
•
Not specified (Ketoconazole) - Not
suspected
•
Acute coronary
syndrome
•
Acute
myocardial
infarction
•
Arteriosclerosis
coronary artery
•
Coronary artery
stenosis
•
Myocardial
ischaemia
•
Respiratory tract
infection
•
Troponin
increased
•
AU00286898 03/08/2011 67 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• • Headache
• Hypertension
AU00287149 09/08/2011 73 - Lucrin (Leuprorelin Acetate) -
Suspected
• • Abdominal pain
Activities of daily
living impaired
•
• Hiatus hernia
Report generated leer12:12:55 AM Page 14 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00287150 09/08/2011 72 - Lucrin (Leuprorelin Acetate) -
Suspected
• Diabetes
mellitus
•
AU00288101 30/08/2011 - - Lucrin (Leuprorelin Acetate) -
Suspected
• Diabetes
mellitus
•
• Pain of skin
• Rash
AU00289537 26/09/2011 - - Lucrin (Leuprorelin Acetate) -
Suspected
• • Cardiac failure
AU00289933 05/10/2011 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Bicalutamide) - Not
suspected
•
• Arthropathy
• Asthma
• Back pain
• Bone pain
• Bronchitis
• Cough
Disturbance in
attention
•
• Headache
• Hot flush
• Lethargy
• Osteoporosis
• Pain
Prostate cancer
metastatic
•
Prostatic specific
antigen
increased
•
AU00291000 26/10/2011 59 - Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Burning
sensation
•
Neuropathy
peripheral
•
• Pain in extremity
• Paraesthesia
AU00294117 03/01/2012 77 - Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Injection site
pain
•
• Skin cancer
AU00298093 28/03/2012 - M Lucrin (Leuprorelin Acetate) -
Suspected
• • Tooth disorder
• Tooth fracture
Report generated leer12:12:55 AM Page 15 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.
Footnotes
i A unique number that permits reference to a particular case
ii The date that information from the original report was entered into the database
iii Age of patient at time of adverse event, '-' if unknown
iv Gender of patient, '-' if unknown
v Medicines reported to have been taken by the patient
vi A description of the adverse event as defined by the Medical Dictionary for Regulatory Activities (MedDRA). You can
use the MedlinePlus medical dictionary <http://www.nlm.nih.gov/medlineplus/mplusdictionary.html> to look up terms.
Database of Adverse Event Notifications List of reports
Case
numberi
Report entry
dateii
Age
(yrs)iii
Genderiv Medicines reported as being takenv MedDRA reaction
termsvi
AU00298973 16/04/2012 79 M Lucrin Depot (Leuprorelin Acetate) -
Suspected
•
Not specified (Acetylsalicylic Acid CT)
- Not suspected
•
Not specified (Allopurinol) - Not
suspected
•
Not specified (Atenolol) - Not
suspected
•
Not specified (Gliclazide) - Not
suspected
•
Not specified (Magnesium Nos) - Not
suspected
•
Not specified (Metformin
Hydrochloride) - Not suspected
•
Not specified (Perindopril) - Not
suspected
•
Confusional
state
•
Injection site
induration
•
Injection site
pain
•
Injection site
swelling
•
• Lethargy
• Pain
• Pyrexia
AU00301119 28/05/2012 - M Lucrin (Leuprorelin Acetate) -
Suspected
• Myocardial
infarction
•
AU00301348 31/05/2012 86 M Lucrin (Leuprorelin Acetate) -
Suspected
• • Pain
AU00301615 05/06/2012 - M Lucrin Depot (Leuprorelin Acetate) -
Suspected
• Myeloid
leukaemia in
remission
•
Report generated leer12:12:55 AM Page 16 of 16
The TGA uses adverse event reports to identify when a safety issue may be present. An adverse event report does not
mean that the medicine is the cause of the adverse event. If you are experiencing an adverse event, or think you may
be experiencing one, please seek advice from a health professional as soon as possible. The TGA strongly advises
people taking prescription medicines not to change their medication regime without prior consultation with a health
professional. Please read all the important information at the beginning of this report.

Re: Fatale Nebenwirkungen durch Downregulation?

heiker, das lese ich nicht, wozu auch.
Du bist hier nicht mehr zur Aufklärung und zur sachlichen Diskussion, es ist ein zugespamte von zig Seiten. Wenn Du Probleme hast, dann suche Dir doch woanders Gleichgesinnte.
Chris betreibt das Forum hier privat. Speicher kostet Geld und die spamst nur noch. Dazu greifst Du Dr.K. an, was in meinen Augen gar nicht geht.
Es ist traurig, wenn man offenbar keinen anderen Lebensinhalt mehr sieht, als sich mit solch Literatur zu befassen. Hier im Forum möchten wir uns über EZP austauschen, nicht nur über Beipackzettel und schon gar nicht in solch einer Weise, wie Du sie hier betreibst.

Chris, kann man da nichts machen, kann mir nicht vorstellen, dass ich hier so ganz alleine mit meiner Meinung bin.

Re: Fatale Nebenwirkungen durch Downregulation?

Hallo Dtift, das verstehe ich jetzt wirklich nicht: Dr. K hat mich gebeten, die Quellen und Daten anzugeben. Was ich auch gemacht habe.
Gruss
heiker

Re: Fatale Nebenwirkungen durch Downregulation?

an alle

Ich habe die meisten Quellen mir angeguckt, vor allen die wichtigste FDA von den USA.

Es gibt keinerlei Hinweis oder Verdacht das Downregulierung Krebs ausloesen kann.

Das da Nebenwirkungen , vor allen Dingen bei Langzeitgebrauch sind, weiss jeder und man muss dann wie bei allen Medikamente abwaegen, ob man die Nebenwirkungen in kauf nimmt oder nicht.

Ich habe immer im Forum von Zoladex abgeraten weil die Wirkung zu lange anhaelt.

Downregulierung ist eine hervorragende Behandlung wenn sie richtig und so niedrig wie moeglich dosiert ist.

Gruss

Dr.K.

Re: Fatale Nebenwirkungen durch Downregulation?

[quote author=heiker link=topic=8140.msg129976#msg129976 date=1350231873]
Hallo Dtift, das verstehe ich jetzt wirklich nicht: Dr. K hat mich gebeten, die Quellen und Daten anzugeben. Was ich auch gemacht habe.
Gruss
heiker
[/quote]

Ich zitiere:

- Herr Dr. K,
Sie antworten auf meine Fragen nicht, z.B. was ist der Wirkmechanismus von GnRH. Wenn er überall verfügbar ist, warum können Sie ihn dann für uns alle nicht ganz allgemeinverständlich beschreiben?

- Hallo Dr. K,

ich möchte Sie bitten, mir meine Fragen zu beantworten bevor Sie mir welche stellen.

- Da Sie sich so sicher sind, bitte ich zu schreiben, wie Sie in Ihrer Praxis feststellen, dass es keine langfristigen Nebenwirkungen gibt. Gibt es z.B. ein Anamneseformular, welches Beschwerden systematisch nach ½ Jahr, 1 Jahr oder 2 Jahren erfasst? Welche Follow ups werden von Ihnen gemacht?

- Lieber Dr. K, bitte informieren Sie sich bei den Aufsichtsichtsbehörden, Bfarm, FDA etc. Dort erhalten Sie Hinweise zu Studien.

Re: Fatale Nebenwirkungen durch Downregulation?

Hallo Claudia,

ich glaube, Du hast nicht alle Beiträge von mir gelesen. Ich bin selbst betroffen.

Mit der Geldmacherei hast Du Recht, leider.

Gruss
heiker

Re: Fatale Nebenwirkungen durch Downregulation?

lieber herr dr. k.

ich möchte mich - auch im namen vieler forumsleserinnen - ganz herzlich dafür bedanken, dass sie uns mit rat und tat zur verfügung stehen, ob spät in den abendstunden oder auch am wochenende. das ist eine grosse hilfestellung für uns und nicht als selbstverständlichkeit anzusehen. es ist schade, dass sie zielscheibe der diskussion einer userin geworden sind.

@all: aus meiner sicht gehört diese person aus dem forum entfernt. richtig ist, dass jeder seine meinung äussern kann, es wurde jedoch sehr viel unsicherheit und auch staub aufgewirbelt. der beipackzettel gibt preis, mit welchen nebenw. zu rechnen ist. daher kann jeder selbst entscheiden. ich kenne auch ganz traurige fälle von schwangeren frauen, bei denen in der schwangerschaft krebs diagnostiziert wurde, bei einer durch einen verkapselten tumor, der zuvor nicht entdeckt wurde und in der SS zu wachsen begann. die hatten aber im leben noch keine DR ganz zu schweigen von einer EZS/EMS. bedingt durch den hohen hormonspiegel in der SS werden unglücklicherweise manche krebsarten zum wachstum angeregt und der krebs explodiert förmlich. in der spontanen schwangerschaft haben wir einen weit aus höheren hormonspiegel als in der "künstlichen".

xenia

Re: Fatale Nebenwirkungen durch Downregulation?

Hallo Leerhuhn und alle

Aber wer ist denn die betroffende Patientin und was ist da passiert ? Ich kann nicht alle Privatmeldungen einsehen und sehe nur was sich hier in Forum abspielt.

Gruss

Dr.K.

Re: Fatale Nebenwirkungen durch Downregulation?

Ich will mich hier nur ganz kurz äußern:

ich bin ein Patientin die Zoladex über 3 Jahr ohne Pause monatlich als Depot gespritzt bekam. Ich habe - außer den zu erwartenden Nebenwirkungen, wie es bei Wechseljahren möglich ist - keine gehabt. Auch diese Wechseljahrsbeschwerden waren für mich nicht von großer Bedeutung. Mir hat das Medikament wahrscheinlich mit das Leben gerettet.
Ich finde es fatal, wie hier Ängste geschürt werden und die Verunsicherung und auch Panik ins Rollen kommt. Das ist sicher nicht Zweck dieses Forums.

Lilly schreibt ganz deutlich in einem ihrer Beiträge - Die Ärzte vermuten, dass die Medikamenten für die EZSP eine Ursache sein könnten - .

Den wahren Grund für ihre Erkrankung wird man nie schlüssig herausfinden können. Jede Krebspatientin hätte dazu gern eine konkrete Antwort - auch ich selbst hätte gern die Ursache gewusst, wie ich an Brustkrebs erkranken konnte - jedoch bleibt man hier ohne Antwort. Ich habe nie geraucht, wenig Alkohol getrunken, Sport gemacht. Zum Erkrankungszeitpunkt keine hormonellen Medikamente eingenommen und bis dato auch keine Behandlung zum Kiwu gehabt.

Die "ganz Schlauen Außenstehenden" die wissen immer, wodurch die Anderen erkranken konnten. Bei mir hieß es auf einmal - du hast bestimmt zu viel Fleisch gegessen, oder die schlimme Pille ( die ich gar nicht einnahm) - .

So ähnlich aufgemacht finde ich auch diese Beiträge zu diesen Depot-Medis. Ich verzichte auf jegliche Aufzählung, ist mir zu aufwändig.
Ich bin nicht nur in diesem Forum "tätig" und ich kenne wenige die mit Depot Medis Probleme haben. Natürlich kenne ich auch Frauen, die Probs hatten. jeder verträgt ein anderes Medikament besser. Vielleicht wären - speziell bei dir heiker - , die Nebenwirkungen mit einem anderen Medikament kaum spürbar gewesen.

Ich habe jetzt Osteoporose - und ich bin dafür leider familiär veranlagt. Ich werde nicht wissen, ob auch die lange Depotgabe hier Mitverursacher ist, denn ich habe keinen Knochenstatus von der Ausgangssituation - sprich vor meiner Krebserkrankung machen lassen. Er wäre vermessen zu behaupten, dass Zoladex ist daran schuld.

Natürlich kann es zu Nebenwirkungen kommen. Die meisten Medikamente haben Nebenwirkungen, jedoch halte ich diese Hexenjagd, die hier stattfindet für völlig übersteuert.
Einen Dr. K. und alle die mit Kiwu-Behandlung zu tun haben, jetzt in Sippenhaft zu nehmen, weil sie fast alle Depot-Medis benutzen ??? Ihnen zu unterstellen, sie klären die Patienten nicht genügend auf ? Man hat den Eindruck, sie werden hier pauschal zu "Verbrechern" erklärt.

Sicher gibt es auch sanfte Downeregulierungen wie Spray´s Synarel o.ä.. Ich denke, viele Kliniken benutzen Depots um einen möglichst "störungsfreien" Ablauf/Planung zu haben. Das ist ja auch im Sinne der Patienten. Auch die Patienten wollen Terminsicherheit in ihrer KIWU-Planung.

Was mich am traurigsten macht ist eigentlich der - für mich unsachliche - Ton, und da meine ich nicht Leerhuhn.

Der Ton wird hier von einer anderen Person hergestellt. Wir sind hier nicht vor dem Richter werte Frau heiker.

Ich will mich hier nur ganz kurz äußern: - na gut, mit kurz , das war wohl nix.

Re: Fatale Nebenwirkungen durch Downregulation?

Mir fehlt die kraft momentan zu wirklich nützlichen Beiträgen. Danke kleiner Löwe für deine besonnene und klare Stellungnahme, der ich mich anschließen möchte. Elina.

Re: Fatale Nebenwirkungen durch Downregulation?

Ich wollte euch über die Riskien der GnRHs informieren, die nicht im Beipackzettel stehen. Das war der Sinn und Zweck meiner Beträge.
Nie habe ich behauptet, dass z.B. bei einem hormonellen Krebs diese Medikamente nicht angezeigt sind. Dann sind sie wahrscheinlich sehr sinnvoll, das kann ich nicht beurteilen. GrRHs waren zunächst nur für Krebs im Einsatz. Krebsmedikamente sind hoch toxisch. Nicht umsonst steht auf dem Beipackzettel, dass eine Schwangerschaft z.B. ausgeschlossen sein muss. Bei manchen steht sogar, dass Frauen, die schwanger werden sollten, diese nicht nehmen sollen.
Warum man das dann für eine Eizellspende, die zu einer Schwangerschaft führen soll, nehmen sollte, hat mir hier noch keiner erklärt.

Dies war mein letzter Beitrag hier öffentlich zu dem Thema. Ihr könnt mich gern weiter per pn anschreiben.

Gruss
heiker

Re: Fatale Nebenwirkungen durch Downregulation?

Bei praktisch jeder IVF / ICSI wird eine DR vorgenommen. Das sind hunderttausende Frauen... Man verfügt über jahrzehntelange Erfahrung. Lest mal den Beipackzettel von Nasentropfen...! Oder von irgend einem vermeintlich harmlosen Medikament...

Heiker ist offensichtlich eine sehr kluge und gebildete Frau (sprachlicher Ausdruck, Orthographie). Aber sie hat im Moment eine "Mission". Sie könnte ja ihre Mission auch mal bei klein putz oder wunschkinder.net posten, statt in einem EZS Forum, in dem die Frauen aus naheliegenden Gründen besonders leicht zu verunsichern sind (Behandlung im Ausland weil bei uns illegal etc.).

Ich hoffe, dass hier bald wieder Ruhe einkehrt. Und: Lasst Euch nicht so schnell verunsichern!

Re: Fatale Nebenwirkungen durch Downregulation?

Die Bemerkung von Heiker dass Downregulierung nicht waehrend oder vor eine Schwangerschaft genommen werden soll ist sehr einfach zu erklaeren. Mit eine Downregulierung werden die Eierstoecke in einen temporaeren Ruhestand versetzt. Falls Sie schwanger sind oder schwanger werden kommt es dann in einem hohem Prozentsatz zu einer Missgeburt da die Hormonelle Unterstuetzung des Eierstocks nicht da ist.
In der Kinderwunschbehandlung wissen wir das natuerlich und deshalb wird Hormonersatz mit Oestrogenen und Progesteron bis zur 11ten , 12ten Woche egegeben.
Das hat alles eine sehr gut fundierte wissentschaftliche Grundlage und funktioniert sehr gut

Dr.K.